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Recently we have reported the effect of (S)-6-aryl urea/thiourea substituted-2-amino-4,5,6,7-tetrahy-
drobenzo[d]thiazole derivatives as potent anti-leukemic agents. To elucidate further the Structure
Activity Relationship (SAR) studies on the anti-leukemic activity of (S)-2,6-diamino-4,5,6,7-tetrahy-
drobenzo[d]thiazole moiety, a series of 2-arlycarboxamide substitutede(S)-6-amino-4,5,6,7-tetrahy-
drobenzo[d]thiazole were designed, synthesized and evaluated for their anti-leukemic activity by trypan
blue exclusion, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), lactate dehydro-
genase (LDH) assays and cell cycle analysis. Results suggest that the position, number and bulkiness of
the substituent on the phenyl ring of aryl carboxamide moiety at 2nd position of 6-amino-4,5,6,7-tetr-
hydrobenzo[d]thiazole play a key role in inhibiting the proliferation of leukemia cells. Compounds with
ortho substitution showed poor activity and with meta and para substitution showed good activity.
 2010 Elsevier Masson SAS. All rights reserved.1. Introduction
Leukemias are uniformly fatal diseases of unknown aetiology
characterized by excessive and abnormal proliferation of primitive
white blood cells and their precursors with inﬁltration into the
various tissues of the body. Leukemias occur in people of all ages.
The leukemias of childhood are the more common one and these
are the cancers of the hematopoietic system, involving in most
cases, malignant transformation of lymphoid progenitor cells and
less commonly transformation of myeloid progenitor cells.
Thiazolemoieties are having variouspharmacological activities, in
general like cyclin dependent kinase inhibitors [1,2], CCR antagonists
[3,4], adenosine receptor antagonists [5e8], anti-inﬂammatory [9]
and antibacterial activities [10]. There are many reports available on
the anti-cancer activity of 2-aminothiazole and benzothiazole
derivatives [11e17]. N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-
hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]-amino)]-1,3-
thiazole-5-carboxamide (BMS-354825, dasatinib, SPRYCEL) is
a novel multi-targeted kinase inhibitor recently approved in
several countries for the treatment of chronic myelogenous
leukemia (CML) as well as Philadelphia chromosome-positive
acute lymphocytic leukemia (ALL). Dasatinib exhibits greater: þ91 821 2500846.
ore.ac.in, rangappaks@gmail.
son SAS. All rights reserved.potency than imatinib mesylate (Gleevec) and inhibits the
majority of kinase mutations in imatinib-resistant CML [18e21].
In our laboratory, we have synthesized a series of 1-((S)-2-
amino-4,5,6,7-tetrahydrobenzo[d] thiazol-6-yl)- 3-(substituted
phenyl)-thiourea and urea derivatives by coupling amine at posi-
tion 6 of (S)-2,6-diaminotetrahydrobenzo[d]thiazole with different
substituted aryl isothiocyanates and isocyanates and identiﬁed
them as potent anti-leukemic agents [22,23]. We continued to seek
alternative templates by converting the amine at position 2 of (S)-
2,6-diaminotetrahydrobenzo[d]thiazole to amide functionality and
to check their efﬁcacy as anti-leukemic agents.2. Chemistry
We synthesized a series of novel class of 2-N-(substituted
phenyl) carbonyl substituted 2,6-diamino-4,5,6,7-tetrahydrobenzo
[d]thiazol hydrochloride derivatives 4(aeh) and evaluated the anti-
leukemic activity of these derivatives. Synthesis of 4(aeh)was done
as outlined in Scheme 1. The key intermediate (S)-2,6-diamino-
4,5,6,7-tetrahydrobenzo[d]thiazole 1 was synthesized using the
earlier reported method [24]. Compound 1 on treatment with Boc
anhydride in presence of potassium carbonate using tetrahydro-
furan as solvent at 5 to 0 C yielded the mono amino protected
compound 2. This mono protected compound on treatment with
different aryl substituted acid chlorides inpresence of triethylamine
using dichloromethane as solvent gave compounds 3(aeh). These
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Scheme 1. Synthesis of 2-(arylcarboxamide)-(S)-6-amino-4,5,6,7-tetrahydrobenzothiazole derivatives.
Table 1
IC50 values of tetrahydrobenzo[d]thiazole derivatives determined by MTT assay.
IC50 (in mM)
Compound K562 CEM
4a 65.73 61.35
4b 17.88 13.78
4c 57.23 56.62
4d 21.01 22.82
4e 4.52 4.52
4f >100 81.24
4g 8.16 9.02
4h 7.72 8.72
D.S. Prasanna et al. / European Journal of Medicinal Chemistry 45 (2010) 5331e53365332compounds on deprotection of boc protection using HCl in ether
yielded the hydrochloride salts of the desired compounds 4(aeh).
The synthesized novel compounds were characterized using the IR,
1H NMR, LCMS and elemental analysis data.
3. Pharmocology
The human leukemia cells, K562 and CEM were selected for the
purpose of preliminary anti-cancer screening of newly synthesized
compounds. To assess the cytotoxicity, we employed trypan blue
dye exclusion assay, MTT assay, LDH assay and cell cycle analysis.
For this, cells growing in log phase were treated with different
concentrations (10, 50 and 100 mM) of 4,5,6,7-tetrahydrobenzo[d]
thiazole derivatives 4(aeh). Further, cytotoxicity compound 4e on
the growth of normal cells was assessed using 293T cells (human
embryonic kidney epithelial cells) using MTT assay.
4. Results and discussion
4.1. Chemistry
The structure of compound 2was conﬁrmed by missing of peak
corresponding to amine at position 6 of tetrahydrobenzothiazole
and the presence of peak corresponding to Boc protected eNH and
a singlet peak corresponding to 9 tert-butyl protons of Boc in the 1H
NMR spectrum of compound 2. The structures of compounds 4
(aeh) were conﬁrmed by the absence of eNH2 peak around
d 6.5 ppm corresponding to the amine at position 2 of tetrahy-
drobenzo[d]thiazole and the presence of a peak around d 12.5 ppm
corresponding to amide proton in the 1H NMR spectrum of the ﬁnal
compounds and a strong absorption at 3395e3435 cm1 for eNH
and 1670e1690 cm1 for C]O in the IR spectrum of the
compounds along with the LCMS and elemental analysis data
conﬁrmed the structure of the novel compounds 4(aeh).4.2. Biology
Newly synthesized 4,5,6,7-tetrahydrobenzo[d]thiazole deriva-
tives 4(aeh) were assessed for cytotoxicity against two human
leukemia cell lines, K562 and CEM. The effective concentrations of
these derivatives required to inhibit K562 or CEM cell growth and
survival were determined ﬁrst by carrying out dose response
experiments using trypan blue dye exclusion assay. In this assay,
the cells were counted at intervals of 24 h till the control cells
attained stationary phase (data not shown). The cell viability was
further assessed by MTT assay. The exposure of these derivatives at
various concentrations for different time points decreased the
number of live cells in a concentration and time dependentmanner.
Among the compounds 4(aeh), compounds 4b, 4d, 4e, 4g and 4h
showed good inhibition against K562 cells with IC50 values of
17.88 mM, 21.01 mM, 4.52 mM, 8.16 mM and 7.72 mM, respectively and
for CEM cells the corresponding IC50 values were 13.78 mM,
22.82 mM, 4.52 mM, 9.02 mM and 8.72 mM respectively (Table 1). The
other compounds namely 4a, 4c and 4f exerted moderate inhibi-
tory activity.
Fig. 1. Time- and dose-dependent LDH release in K562 cells treated with 4e. K562 cells
were incubated for 24 h with different concentrations of 4e. Release of LDH in the
medium was measured at 490 nm. Results are presented as percentage of LDH release.
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substituent on the phenyl group of 1-((S)-2-amino-4,5,6,7-tetra-
hydrobenzo[d]thiazol-6-yl)-3-(substituted phenyl)-thiourea and
urea derivatives playing a key role in the anti-leukemic activity of
these compounds [22,23]. Electron withdrawing groups on the
phenyl ring of the aryl thiourea/urea moiety showed potent
activity. Here, in these compounds 4(aeh), we observed that the
position and size of the substituent on the phenyl ring of aryl car-
boxamide playing the key role. Comparing the IC50 values of the
newly synthesized derivatives 4(aeh), we were able to draw some
of the structure activity relationships (SAR). Compound 4a, which is
having unsubstituted phenyl ring showed moderate activity with
an IC50 value of 65.73 mM against K562 cells and 61.35 mM against
CEM cells. Compound 4c with 2-ﬂuoro substitution on phenyl ring
also showed moderate activity with an IC50 value of 57.23 mM
against K562 cells and 56.62 mM against CEM cells. Compound 4f
having 2,6-diﬂuoro substitution showed poor activity with IC50
values of >100 mM for K562 cells and 81.24 mM for CEM cells.
Compounds 4b and 4d having methoxy and bromo substitution
respectively at the meta position on the phenyl ring showed good
activity. The corresponding IC50 values are 17.88 mM and 21.02 mM
respectively for K562 cells and 13.78 and 22.82 mM respectively for
CEM cells. Comparing the activity of 4b and 4d with that of
compounds 4c and 4f, we observed that, the position of the
substitution is playing a key role in the inhibitory activity.
Compound 4g having a meta dinitro (3,5-dinitro) substitution
showed good activity with IC50 values of 8.16 mM and 9.02 mM
respectively for K562 and CEM cells. The activity of compound 4g is
good compared to that of compounds 4b and 4d with mono
methoxy and mono bromo substitution at meta positions respec-
tively. This may be due to the substitution at meta position and also
the presence of the bulkiness of nitro group.
Compound 4h having ortho and para dichloro substitution also
showed good activity with IC50 values of 7.72 mM and 8.72 mM
respectively for K562 and CEM cells which is comparable with that
of compound 4g with meta dinitro substitution. Even though the
chloro group is small compared to nitro groups, the activity may be
due to the presence of chloro at ortho position.
Compound 4e having a tert-butyl substitution at para position
showed more potent and better activity compared to all other
molecules in the series. Since we observed the complete death of
cells at 10 mM of 4e, we tested at low concentrations to determine
the IC50 value and it was found to be 4.52 mM for both the cell lines
(data not shown). The effect of 4e on cell viability was also
a concentration and time dependent manner like other molecules
in the series tested. The potency of this molecule could be due to
the bulkiness of the tert-butyl group. Further, to investigate the
cytotoxicity of 4e we carried out LDH release assay, which is an
indicator of cell death at early time point of 24 h at low concen-
trations (Fig. 1). The data showed that 4e induces the release of LDH
into the media in a concentration dependent manner.
In addition, the results from trypan blue exclusion assay andMTT
assay showed that 4e signiﬁcantly reduced the number of live cells.
Hence, to explore the effect of 4e on cell cycle distribution of K562
cells, we studied cell cycle distribution by ﬂuorescence activated cell
sorting (FACS). Thehistogramof vehicle control (DMSO) treated cells
showed a standard cell cycle pattern,which includeG1 andG2peaks
separated by S phase peak (Fig. 2). G0/G1 peak (mostly dead cells)
was either absent or not prominent. Although we were not able to
visualize the prominent arrest at any stage of the cell cycle,wenoted
the accumulation of subploid cells, the subG1 phase (G0/G1), and
decline of both G1 and G2/M (Fig. 2A and B) phases at 10 mMwhen
comparedwithuntreated cells.Wedidnot seeprominent changes in
any phase of cell cycle at lowconcentrations and our studies suggest
that signiﬁcant growth inhibition by 4e could be due to apoptosis.Further, to determine the cytotoxic effect of 4e on normal cells,
293T cells (human embryonic kidney epithelial cells) were treated
with 4e at different concentrations (1e5 mM) and viability of cells
was determined by MTT assay. Data reveals that 4e has no signiﬁ-
cant effect on normal cells at tested concentrations (Fig. 3).
5. Conclusions
From the structure activity relationship studies, we observed
that the position and number of the substituents on the phenyl ring
of aryl carboxamide moiety in the tetrahydrobenzothiazole deriv-
atives 4(aeh) are important in reasoning the activity. Compounds
with no substitution and/or ortho substitution are shown poor
inhibition of proliferation of leukemia cells, whereas the
compounds with meta and para substitution the reasonable
inhibiting the proliferation of leukemia cells. Bulky substituents at
the meta and ortho position also play a dominant role in inhibiting
the leukemic cells proliferation.
6. Experimental Section
IR spectrawere recorded using a Jasco FTIR-2008 series. 1H NMR
spectra were recorded on Shimadzu AMX 400-Bruker, 400 MHz
spectrometer using DMSO as a solvent and TMS as internal stan-
dard (chemical shift in d ppm). Spin multiplets are given as s
(singlet), d (doublet), t (triplet) and m (multiplet). Mass and purity
were recorded on an LCeMSD-Trap-XCT. Elemental (CHNS) anal-
yses were obtained on Vario EL III Elementar. Silica gel column
chromatography was performed using Merck 7734 silica gel
(60e120 mesh) and Merck made TLC plates.
6.1. Synthesis of 2-(arylcarboxamide)-(S)-6-amino-4,5,6,7-
tetrahydrobenzothiazole derivatives
6.1.1. Synthesis of (S)-tert-butyl 2-amino-4,5,6,7-tetrahydrobenzo
[d]thiazol-6-ylcarbamate 2
To the solution of compound (S)-2,6-diamino-4,5,6,7-tetrahy-
drobenzo[d]thiazol 1 (3 g, 0.018 mol) in tetrahydrofuran, potassium
carbonate (4.9 g, 0.035 mol) was added followed by Boc anhydride
(3.8 g, 0.0175mol) dropwise at5 C and stirred at5 to 0 C for 6 h.
Completion of reactionwasmonitored using TLC. After completion of
reaction, tetrahydrofuran was removed under reduced pressure.
Waterwas added and the reactionmixturewas extracted thriceusing
ethyl acetate (3 50mL). The combined organic layerwas dried over
anhydrous sodium sulphate. Ethyl acetate was removed under
reduced pressure and puriﬁed using silica gel (60e120 mesh) using
Fig. 2. Cell cycle analysis of K562 cells treated with 4e. K562 cells (0.75  105 cells/ml) were incubated at 37 C with 4e (1, 5 and 10 mM). Following 48 h of incubation, cells were
ﬁxed and stained with propidium iodide and subjected to FACS analysis. Panel A and B show histograms comparing the effect of 4e at speciﬁc cell cycle stages. In the Panel A, the
ﬁrst histogram represents DMSO treated cells. Panel B show the quantiﬁcation of cells in different stages of cell cycle followed by treatment with 4e.
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d6, 400MHz) d: 6.94 (d,1H,NH), 6.65 (s, 2H,NH2), 3.63 (bs,1H,eCHe),
2.70 (m,1H,eCH2e), 2.56 (m, 2H,eCH2e), 2.37 (m,1H,eCH2e),1.86
(t, 1H, eCH2e), 1.37 (s, 9H, e(CH3)3). Elemental Analysis: Found: C,
53.63;H, 7.06;N,15.52; S,12.01; Calculated for C12H19N3O2S: C, 53.51;
H, 7.11; N, 15.60; S, 11.90.
6.1.2. General procedure for the synthesis 2-N-aryl carbonyl
substituted 2,6-diamino-4,5,6,7-tetrahydrobenzo[d]thiazol
hydrochloride 4(aeh)
To a solution of tert-butyl (S)-2-amino-4,5,6,7-tetrahydrobenzo
[d]thiazol-6-ylcarbamate 2 (1 eq) in dichloromethane, triethyl-
amine (3 eq)was added and cooled to 0 C, respective acid chloridesFig. 3. Effect of 4e on the growth of normal cells. 293T cells exposed to different
concentrations of 4e were incubated with MTT and absorbance was measured at
570 nm.(1eq) were added at cold condition and stirred at room temperature
for 6e8 h (completion of reaction was conﬁrmed by TLC). After
completion of the reaction, the reaction mixture was concentrated
and water was added and extracted thrice using ethyl acetate. The
combined ethyl acetate layer was washed with brine solution and
dried over anhydrous sodium sulphate. Ethyl acetate was evapo-
rated under reduced pressure and the crude product obtained was
puriﬁed by silica gel (60e120mesh) column to get the compounds 3
(aeh). To the solution of compound 3(aeh) in dry ether (3 mL) at
0 C saturated HCl in ether (1 ml) was added slowly and stirred at
0 C for 3 h, white solid formedwas ﬁltered and dried under vaccum
to get the compounds 4(aeh).
6.1.2.1. Synthesis of (S)-N-(6-amino-4,5,6,7-tetrahydrobenzo[d]thia-
zol-2-yl)benzamide hydrochloride 4a. The product 4awas obtained
by reaction of compound 2 (0.40 g,1.5 mmol) with benzoyl chloride
(0.21 g, 1.5 mmol) and triethylamine (0.45 g, 4.5 mol) in dichloro-
methane (5 ml) and then cleaving the Boc protection using HCl in
ether using the general experimental procedure as described. Yield
0.35 g (76%). IR (KBr, cm1): 1688. 1H NMR (DMSO-d6, 400 MHz) d:
12.41 (bs,1H, NH), 8.44 (d, 3H, NH3þ salt), 7.65 (m, 5H, Ar-H), 3.53 (bs,
1H, eCHe), 3.14e3.09 (m, 1H, eCH2e), 2.83e2.75 (m, 1H, eCH2e),
2.73e2.65 (m, 2H, eCH2e), 2.19 (t, 1H, eCH2e), 1.98 (t, 1H, eCH2e).
MS (ESIþ ion):m/z¼ 310.2. Elemental Analysis: Found: C, 54.34; H,
5.27; N, 13.65; S, 10.22; Calculated for C14H16ClN3OS: C, 54.27; H,
5.21; N, 13.56; S, 10.35.
6.1.2.2. Synthesis of (S)-N-(6-amino-4,5,6,7-tetrahydrobenzo[d]thia-
zol-2-yl)-3-methoxy benzamide hydrochloride 4b. The product 4b
was obtained by reaction of compound 2 (0.40 g, 1.5 mmol) with 3-
methoxy benzoyl chloride (0.26 g, 1.5 mmol) and triethylamine
(0.45 g, 4.5mol) in dichloromethane (5ml) and then cleaving the Boc
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dure as described. Yield 0.40 g (78%). IR (KBr, cm1): 1690,1237,1112.
1H NMR (DMSO-d6, 400 MHz) d: 12.48 (bs, 1H, NH), 8.49 (d, 3H, NH3þ
salt), 7.65 (m, 1H, Ar-H), 7.44 (m, 2H, Ar-H), 7.12 (s, 1H, Ar-H), 3.92 (s,
3H,eOCH3), 3.57 (bs,1H,eCHe), 3.13e3.09 (m,1H,eCH2e), 2.8e2.76
(m,1H,eCH2e), 2.71e2.64 (m, 2H, eCH2e), 2.18 (t, 1H, eCH2e), 1.96
(t, 1H, eCH2e). MS (ESI þ ion): m/z ¼ 340.3. Elemental Analysis:
Found: C, 52.91; H, 5.36; N, 12.42; S, 9.37; Calculated for
C15H18ClN3O2S: C, 53.01; H, 5.34; N, 12.36; S, 9.44.
6.1.2.3. Synthesis of (S)-N-(6-amino-4,5,6,7-tetrahydrobenzo[d]thia-
zol-2-yl)-2-ﬂuorobenzamide hydrochloride 4c. The product 4c was
obtained by reaction of compound 2 (0.40 g, 1.5 mmol) with 2-
ﬂuoro benzoyl chloride (0.24 g, 1.5 mmol) and triethylamine
(0.45 g, 4.5 mmol) in dichloromethane (5 ml) and then cleaving the
Boc protection using HCl in ether using the general experimental
procedure as described. Yield 0.37 g (75%).
IR (KBr, cm1): 1688, 1033. 1H NMR (DMSO-d6, 400 MHz) d: 12.41
(bs,1H, NH), 8.41 (d, 3H, NH3þ salt), 7.74e7.69 (m,1H, Ar-H), 7.65e7.59
(m,1H, Ar-H), 7.38e7.32 (m, 2H, Ar-H), 3.53 (bs,1H,eCHe), 3.15e3.09
(m, 1H, eCH2e), 2.83e2.77 (m, 1H, eCH2e), 2.73e2.64 (m,
2H, eCH2e), 2.17 (t, 1H, eCH2e), 1.97 (t, 1H, eCH2e). MS (ESIþ ion):
m/z¼ 328.1. Elemental Analysis: Found: C, 51.36; H, 4.54; N,12.88; S,
9.75; Calculated for C14H15ClFN3OS: C, 51.30;H, 4.61; N,12.82; S, 9.78.
6.1.2.4. Synthesis of (S)-N-(6-amino-4,5,6,7-tetrahydrobenzo[d]thia-
zol-2-yl)-3-bromobenzamide hydrochloride 4d. The product 4d was
obtained by reaction of compound 2 (0.40 g, 1.5 mmol) with 3-
bromo benzoyl chloride (0.33 g, 1.5 mmol) and triethylamine
(0.45 g, 4.5 mmol) in dichloromethane (5 ml) and then cleaving the
Boc protection using HCl in ether using the general experimental
procedure as described. Yield 0.38 g (67%).
IR (KBr, cm1): 1686, 688. 1H NMR (DMSO-d6, 400 MHz) d: 12.41
(bs, 1H, NH), 8.41 (d, 3H, NH3þ salt), 7.76 (m, 1H, Ar-H), 7.52 (m, 2H,
Ar-H), 7.34 (s, 1H, Ar-H), 3.50 (bs, 1H, eCHe), 3.17e3.11 (m, 1H,
eCH2e), 2.83e2.77 (m,1H,eCH2e), 2.75e2.65 (m, 2H,eCH2e), 2.19
(t, 1H, eCH2e), 1.95 (t, 1H, eCH2e). MS (ESI þ ion): m/z ¼ 389.0.
Elemental Analysis: Found: C, 43.29; H, 3.86; N, 10.89; S, 8.15;
Calculated for C14H15BrClN3OS: C, 43.26; H, 3.89; N, 10.81; S, 8.25.
6.1.2.5. Synthesis of (S)-N-(6-amino-4,5,6,7-tetrahydrobenzo[d]thia-
zol-2-yl)-4-tert-butylbenzamide hydrochloride 4e. The product 4e
was obtained by reaction of compound 2 (0.40 g, 1.5 mmol) with 4-
tert-butyl benzoyl chloride (0.30 g, 1.5 mmol) and triethylamine
(0.45 g, 4.5 mmol) in dichloromethane (5 ml) and then cleaving the
Boc protection using HCl in ether using the general experimental
procedure as described. Yield 0.44 g (79%).
IR (KBr, cm1): 1684,1399. 1HNMR (DMSO-d6, 400MHz) d: 12.41
(bs,1H, NH), 8.41 (d, 3H, NH3þ salt), 7.79 (d, 2H, Ar-H), 7.54 (d, 2H, Ar-
H), 3.53 (bs, 1H, eCHe), 3.14e3.09 (m, 1H, eCH2e), 2.84e2.76 (m,
1H, eCH2e), 2.71e2.62 (m, 2H,eCH2e), 2.15 (t, 1H, eCH2e), 1.99 (t,
1H, eCH2e), 1.33 (s, 9H, (eCH3)3). MS (ESI þ ion): m/z ¼ 366.2.
Elemental Analysis: Found: C, 59.14; H, 6.66; N, 11.42; S, 8.69.;
Calculated for C18H24ClN3OS: C, 59.08; H, 6.61; N, 11.48; S, 8.76.
6.1.2.6. Synthesis of (S)-N-(6-amino-4,5,6,7-tetrahydrobenzo[d]thia-
zol-2-yl)-2,6-diﬂuoro benzamide hydrochloride 4f. The product 4f
was obtained by reaction of compound 2 (0.40 g, 1.5 mmol) with
2,6-diﬂuoro benzoyl chloride (0.27 g, 1.5 mmol) and triethylamine
(0.45 g, 4.5 mmol) in dichloromethane (5 ml) and then cleaving the
Boc protection using HCl in ether using the general experimental
procedure as described. Yield 0.41 g (78%). IR (KBr, cm1): 1689,
1167. 1H NMR (DMSO-d6, 400 MHz) d: 12.45 (bs, 1H, NH), 8.46 (d,
3H, NH3þ salt), 7.65 (m, 1H, Ar-H), 7.26 (t, 2H, Ar-H), 3.53 (bs, 1H,
eCHe), 3.16e3.10 (m, 1H, eCH2e), 2.85e2.79 (m, 1H, eCH2e),2.77e2.67 (m, 2H, eCH2e), 2.17 (t, 1H, eCH2e), 1.98 (t, 1H, eCH2e).
MS (ESIþ ion):m/z¼ 346.1. Elemental Analysis: Found: C, 48.52; H,
3.97; N, 12.11; S, 9.19; Calculated for C14H14ClF2N3OS: C, 48.63; H,
4.08; N, 12.15; S, 9.27.
6.1.2.7. Synthesis of (S)-N-(6-amino-4,5,6,7-tetrahydrobenzo[d]thia-
zol-2-yl)-3,5-dinitro benzamide hydrochloride 4g. The product 4g
was obtained by reaction of compound 2 (0.40 g, 1.5 mmol) with
3,5-dinitro benzoyl chloride (0.34 g, 1.5 mmol) and triethylamine
(0.45 g, 4.5 mol) in dichloromethane (5 ml) and then cleaving the
Boc protection using HCl in ether using the general experimental
procedure as described. Yield 0.47 g (78%). IR (KBr, cm1): 1690,
1545,1338. 1H NMR (DMSO-d6, 400 MHz) d: 12.49 (bs, 1H, NH), 8.59
(s, 2H, Ar-H), 7.48 (s, 1H, Ar-H), 8.39 (d, 3H, NH3þ salt), 3.53 (bs,
1H, eCHe), 3.19e3.12 (m, 1H, eCH2e), 2.85e2.78 (m, 1H, eCH2e),
2.74e2.66 (m, 2H, eCH2e), 2.18 (t, 1H, eCH2e), 1.97 (t, 1H, eCH2e).
MS (ESIþ ion):m/z¼ 400.1. Elemental Analysis: Found: C, 42.014 H,
3.47; N, 17.58; S, 7.93.; Calculated for C14H14ClN5O5S: C, 42.06; H,
3.53; N, 17.52; S, 8.02.
6.1.2.8. Synthesis of (S)-N-(6-amino-4,5,6,7-tetrahydrobenzo[d]thia-
zol-2-yl)-2,4-dichloro benzamide hydrochloride 4h. The product 4h
was obtained by reaction of compound 2 (0.40 g, 1.5 mmol) with
2,4-dichloro benzoyl chloride (0.31 g, 1.5 mmol) and triethylamine
(0.45 g, 4.5 mmol) in dichloromethane (5 ml) and then cleaving
the Boc protection using HCl in ether as given in general proce-
dure. Yield 0.39 g (68%). IR (KBr, cm1): 1686, 722. 1H NMR
(DMSO-d6, 400 MHz) d: 12.47 (bs, 1H, NH), 8.39 (d, 3H, NH3þ salt),
7.39 (s, 1H, Ar-H), 7.23 (m, 2H, Ar-H), 3.49 (bs, 1H, eCHe),
3.16e3.11 (m, 1H, eCH2e), 2.84e2.75 (m, 1H, eCH2e), 2.75e2.67
(m, 2H, eCH2e), 2.14 (t, 1H, eCH2e), 1.99 (t, 1H, eCH2e). MS
(ESI þ ion): m/z ¼ 379.0. Elemental Analysis: Found: C, 44.37; H,
3.60; N, 11.21; S, 8.41; Calculated for C14H14Cl3N3OS: C, 44.40; H,
3.73; N, 11.10; S, 8.47.6.2. Biological study
The human chronic myelogenous leukemia (CML) K562 and
CEM were selected for the purpose of preliminary anti-cancer
screening of newly synthesized compounds. To assess the cyto-
toxicity, we employed trypan blue dye exclusion assay, MTT assay,
LDH assay and FACS analysis. For this, cells growing in log phase
were treated with different concentrations (as mentioned in
respective assays) of 4,5,6,7-tetrahydrobenzo[d]thiazole deriva-
tives 4(aeh). Assays were carried out in duplicate in at least three
independent experiments.
6.2.1. Cell lines and culture
Human cell lines, K562 and CEM were purchased from National
Center for Cell Science, Pune, India. Cells were grown in RPMI 1640
supplemented with 10% heat-inactivated fetal bovine serum (FBS),
100 U/mL of Penicillin, and 100 mg of streptomycin/ml and incu-
bated at 37 C in a humidiﬁed atmosphere containing 5% CO2.
6.2.2. Trypan blue exclusion assay
Cell viability was monitored by the Trypan blue exclusion
assay as reported earlier [25]. Brieﬂy, K562 or CEM cells, growing
in exponential phase were seeded at a density of 0.75  105 cells/
ml in a 6-well tissue culture plate for 24 h and cells were
exposed to a different concentrations (10, 50, and 100 mM) of 4
(aeh). Cells were collected at intervals of 24 h and resuspended
in 0.4% Trypan blue and further incubated for 5 min after which
the number of viable cells was estimated in a haemocytometer
chamber.
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Cell proliferation was further assessed by 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, which is
based on the ability of viable cells to metabolize a yellow tetrazo-
lium salt to violet formazan. Exponentially growing K562 or CEM
cells (1  104 cells/well) were plated in duplicates and incubated
with 10, 50 and 100 mMof 4(aeh). Cells were harvested after 48 and
72 h of treatment and incubated with MTT (0.5 mg/ml). The
percentage cell proliferation was calculated and IC50 values
(concentration of compound causing 50% inhibition of cell growth)
were estimated after 72 h of compound treatment.
6.2.4. LDH release assay
The cytotoxicity of the compound 4e was further assessed by
LDH release assay, which is an indicator of membrane integrity
and hence cell injury. LDH assay was performed as per standard
protocols [26] to estimate the LDH release in the culture media
following the treatment of 4e at 1, 5 and 10 mM concentrations on
K562 cells for 24 h. The LDH release was measured. Percentage
of LDH release was calculated and plotted as graph as shown in
Fig. 1.
6.2.5. Cell cycle analysis
Cellular DNA content of K562 cells followed by 4e treatment was
measured by ﬂow cytometry. Approximately 0.75  105 cells/ml
were cultured and treated with 1, 5 and 10 mM concentrations of 4e.
Cells were harvested after 24 h of treatment, washed, ﬁxed in 70%
ethanol and incubated with RNase A (SigmaeAldrich, USA). Pro-
pidium iodide (PI, 50 mg/ml, SigmaeAldrich, USA) was added half
an hour before acquiring the ﬂow cytometric reading (FACScan, BD
Biosciences, USA). A minimum of 10,000 cells were acquired per
sample and histograms were analyzed by using WinMDI 2.8
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